The Guild Pharmacy Academy has launched a new course on rivaroxaban.
With the end of the CPD year fast approaching, the Guild Pharmacy Academy has announced another new online course to assist pharmacists in meeting their continuing professional development requirements.
In this course the Guild Pharmacy Academy has partnered with Bayer Australia Limited to develop an online learning course which examines the use of the anticoagulant drug rivaroxaban (XARELTO).
The course provides pharmacists with an understanding of the purpose and benefits of anticoagulant therapy in non-valvular atrial fibrillation and venous thromboembolism, the characteristics of rivaroxaban and important points that pharmacists should consider when providing counselling to patients receiving rivaroxaban.
Anthony Tassone, the President of the Pharmacy Guild of Australia, Victoria Branch, and a community pharmacist, says patients who are new to anticoagulant therapy or have switched from another anticoagulant agent often have many questions and concerns.
“This can be a worrying time for some of our patients,” he says.
“A new medicine can be concerning for some patients and their families, many have a range of questions about how the medicine can work, the dosage and what side effects it may have.
“Engaging with the patient or their carer and providing them with clear guidance and advice on how to take this medicine can improve their adherence and ensure that they are achieving the best possible health outcomes.”
Information provided in this course, including the mechanism of action, key clinical characteristics and potential adverse effects of rivaroxaban will assist pharmacists in providing effective initial and ongoing counselling to patients prescribed rivaroxaban.
The completion of this online course will attract 2 Group Two CPD Credits following the successful completion of an assessment and is available on the Guild Academy’s myCPD site.
The Guild Pharmacy Academy has thanked Bayer Australia Limited for its support and input of expertise in the development of this course.